## Jonathan Chou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7783045/publications.pdf

Version: 2024-02-01

| 30       | 5,572          | 17 h-index   | 29             |
|----------|----------------|--------------|----------------|
| papers   | citations      |              | g-index        |
| 30       | 30             | 30           | 11497          |
| all docs | docs citations | times ranked | citing authors |

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab<br>Vedotin-resistant Cells. European Urology Oncology, 2022, 5, 714-718.   | 5.4  | 32        |
| 2  | Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer, 2022, 128, 1194-1205.                    | 4.1  | 26        |
| 3  | CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical Cancer Research, 2022, 28, 3066-3075.                 | 7.0  | 10        |
| 4  | Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clinical Cancer Research, 2021, 27, 1305-1315.  | 7.0  | 18        |
| 5  | Differential treatment outcomes in <i>BRCA1/2</i> â€, <i>CDK12</i> â€, and <i>ATM</i> â€mutated metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 1965-1973.                                  | 4.1  | 15        |
| 6  | Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clinical Cancer Research, 2021, 27, 5123-5130.                             | 7.0  | 65        |
| 7  | Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 2021, 79, 717-721.     | 1.9  | 13        |
| 8  | An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nature Communications, 2021, 12, 4601.  | 12.8 | 18        |
| 9  | Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.  | 1.9  | 65        |
| 10 | The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.   | 21.4 | 198       |
| 11 | Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.   | 7.0  | 10        |
| 12 | Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discovery, 2020, 10, 351-370.   | 9.4  | 162       |
| 13 | Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.<br>Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1446-1452.                             | 4.9  | 2         |
| 14 | DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.                                  | 7.0  | 17        |
| 15 | Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clinical Cancer Research, 2019, 25, 2450-2457.  | 7.0  | 52        |
| 16 | MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Science Alliance, 2019, 2, e201800226.  | 2.8  | 61        |
| 17 | HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E992-E1001. | 7.1  | 74        |
| 18 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.   | 28.9 | 459       |

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Prostate cancer in the era of "Omic―medicine: recognizing the importance of DNA damage repair pathways. Annals of Translational Medicine, 2018, 6, 161-161.                   | 1.7  | 7         |
| 20 | Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 2018, 173, 1770-1782.e14.  | 28.9 | 400       |
| 21 | Metalloproteinases: a Functional Pathway for Myeloid Cells. Microbiology Spectrum, 2016, 4, .   | 3.0  | 20        |
| 22 | Respiratory Failure in a Woman 8 Months After an Allogeneic Stem Cell Transplant. JAMA Oncology, 2016, 2, 1651.   | 7.1  | 1         |
| 23 | Electrocardiography Evolution in a Woman Presenting With Alcohol Withdrawal Seizures and Cocaine Use. JAMA Internal Medicine, 2016, 176, 693.                                 | 5.1  | 1         |
| 24 | The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. Journal of Biological Chemistry, 2015, 290, 3803-3813. | 3.4  | 29        |
| 25 | Remodelling the extracellular matrix in development and disease. Nature Reviews Molecular Cell Biology, 2014, 15, 786-801.  | 37.0 | 3,082     |
| 26 | GATA3 suppresses metastasis and modulates the tumour microenvironment by regulatingÂmicroRNA-29b expression. Nature Cell Biology, 2013, 15, 201-213.                          | 10.3 | 322       |
| 27 | microRNA-mediated regulation of the tumor microenvironment. Cell Cycle, 2013, 12, 3262-3271.  | 2.6  | 117       |
| 28 | MicroRNAs Play a Big Role in Regulating Ovarian Cancer–Associated Fibroblasts and the Tumor Microenvironment. Cancer Discovery, 2012, 2, 1078-1080.                           | 9.4  | 35        |
| 29 | GATA3 in development and cancer differentiation: Cells GATA have it!. Journal of Cellular Physiology, 2010, 222, 42-49.   | 4.1  | 261       |
| 30 | Metalloproteinases: a Functional Pathway for Myeloid Cells. , 0, , 649-658.   |      | 0         |